Dataset Information
Peter MacCallum Cancer Centre Research Data Access Committee
Ontology highlight
ABSTRACT:
PROVIDER: EGAC00001001404 | EGA |
REPOSITORIES: EGA
Publications
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20200124 4
<h4>Introduction</h4>Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC). However, the mechanisms of resistance to these agents have not yet been described.<h4>Methods</h4>Analysis was performed of circulating tumor DNA and tissue in patients with RET fusion-positive NSCLC ...[more]
